Related Experiment Video
Updated: May 25, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary
Paul Kah Hing Ling1, Fernando Civeira, Andrei Gheorghe Dan
1School of Medicine and Health Sciences, Monash University, 80100 Johor Bahru, Malaysia. pkhling@yahoo.co.uk
Insights
Switching to ezetimibe/simvastatin significantly improved LDL-C reduction in high-risk patients compared to increasing atorvastatin. This combination therapy offers a superior option for achieving cholesterol targets when statins alone are insufficient.
Area of Science:
- Cardiovascular medicine
- Pharmacology
- Lipid metabolism
Background:
- Many high-cardiovascular-risk patients with hypercholesterolemia fail to reach LDL-C treatment goals with statins alone.
- A significant unmet need exists for more effective lipid-lowering strategies in this population.
- This study addresses the efficacy of combination therapy versus intensified statin therapy.
Purpose of the Study:
- To compare the efficacy of switching to ezetimibe/simvastatin versus doubling the atorvastatin dose in lowering LDL-C.
- To assess the achievement of LDL-C treatment targets in high cardiovascular risk patients.
- To evaluate the safety and tolerability of both treatment regimens.
Main Methods:
- Randomized controlled trial involving 250 high-risk adults with hypercholesterolemia pretreated with atorvastatin 20 mg.
- Participants were randomized to receive either ezetimibe/simvastatin 10/40 mg or atorvastatin 40 mg for 6 weeks.
- Lipid changes were analyzed using constrained longitudinal data analysis; goal achievement was assessed via logistic regression.
Main Results:
- Switching to ezetimibe/simvastatin resulted in significantly greater reductions in LDL-C (-26.81% vs. -11.81%), total cholesterol, non-HDL-C, and Apo B compared to doubling atorvastatin (p ≤ 0.002).
- A significantly higher percentage of patients achieved LDL-C goals (<1.81 mmol/L, <2.00 mmol/L, <2.59 mmol/L) with ezetimibe/simvastatin (p < 0.001).
- The safety profiles of both treatment groups were comparable.
Conclusions:
- Combination therapy with ezetimibe/simvastatin is significantly more effective than doubling atorvastatin dose for LDL-C lowering in patients not at goal.
- Switching to ezetimibe/simvastatin facilitates greater achievement of LDL-C targets.
- Both treatment strategies were generally well-tolerated.
Background:
A considerable number of patients with severely elevated LDL-C do not achieve recommended treatment targets, despite treatment with statins. Adults at high cardiovascular risk with hypercholesterolemia and LDL-C ≥ 2.59 and ≤ 4.14 mmol/L (N = 250), pretreated with atorvastatin 20 mg were randomized to ezetimibe/simvastatin 10/40 mg or atorvastatin 40 mg for 6 weeks. The percent change in LDL-C and other lipids was assessed using a constrained longitudinal data analysis method with terms for treatment, time, time-by-treatment interaction, stratum, and time-by-stratum interaction. Percentage of subjects achieving LDL-C < 1.81 mmol/L, < 2.00 mmol/L, or < 2.59 mmol/L was assessed using a logistic regression model with terms for treatment and stratum. Tolerability was assessed.
Results:
Switching to ezetimibe/simvastatin resulted in significantly greater changes in LDL-C (-26.81% vs.-11.81%), total cholesterol (-15.97% vs.-7.73%), non-HDL-C (-22.50% vs.-10.88%), Apo B (-17.23% vs.-9.53%), and Apo A-I (2.56% vs.-2.69%) vs. doubling the atorvastatin dose (all p ≤ 0.002), but not HDL-C, triglycerides, or hs-CRP. Significantly more subjects achieved LDL-C < 1.81 mmol/L (29% vs. 5%), < 2.00 mmol/L (38% vs. 9%) or < 2.59 mmol/L (69% vs. 41%) after switching to ezetimibe/simvastatin vs. doubling the atorvastatin dose (all p < 0.001). The overall safety profile appeared generally comparable between treatment groups.
Conclusions:
In high cardiovascular risk subjects with hypercholesterolemia already treated with atorvastatin 20 mg but not at LDL-C < 2.59 mmol/L, switching to combination ezetimibe/simvastatin 10/40 mg provided significantly greater LDL-C lowering and greater achievement of LDL-C targets compared with doubling the atorvastatin dose to 40 mg. Both treatments were generally well-tolerated.
Trial Registration:
Registered at clinicaltrials.gov: NCT00782184.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:15Bioavailability Study Design: Healthy Subjects Versus Patients